Mechanisms, Models, Measurement, & Management in Pain Research (R01 and R21)

Mechanisms, Models, Measurement, & Management in Pain Research (R01 and R21) is sponsored by National Center for Complementary and Integrative Health (NCCIH). This opportunity supports mission-aligned projects and measurable outcomes.

Expired PA-16-187: Mechanisms, Models, Measurement, and Management in Pain Research (R21) This notice has expired. Check the NIH Guide for active opportunities and notices. Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) of Participating Organizations National Cancer Institute ( NCI ) National Institute of Nursing Research ( NINR ) National Institute on Aging ( NIA ) National Institute of Arthritis and Musculoskeletal and Skin Diseases ( NIAMS ) National Institute on Drug Abuse ( NIDA ) National Institute of Dental and Craniofacial Research ( NIDCR ) National Institute of Neurological Disorders and Stroke ( NINDS ) National Center for Complementary and Integrative Health ( NCCIH ) National Institute on Minority Health and Health Funding Opportunity Title Mechanisms, Models, Measurement, & Management in Pain Research (R21) R21 Exploratory/Developmental Research Grant November 07, 2017 - This PA has been reissued as PA-18-159 for due dates on or after January 25, 2018.

May 10, 2017 - New NIH "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates On or After January 25, 2018. See NOT-OD-17-062 . May 3, 2016 - Notice of National Cancer Institute's Participation in PA-16-187.

See Notice NOT-CA-16-043 . Funding Opportunity Announcement (FOA) Number Companion Funding Opportunity PA-16-188 , R01 Research Project Grant Additional Information on Eligibility . Catalog of Federal Domestic Assistance (CFDA) Number(s) 93.

361; 93. 866; 93. 846; 93.

279; 93. 121; 93. 853; 93.

213; Funding Opportunity Purpose The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs.

New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved.

Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

Open Date (Earliest Submission Date) Letter of Intent Due Date(s) Any due dates on or after Jan 25, 2018 must use reissued FOA. dates , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. AIDS Application Due Date(s) dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

New Date January 24, 2018 per reissuance of FOA (Original Expiration Date: May 8, 2019) Required Application Instructions It is critical that applicants follow the instructions in (R&R) Application Guide , except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced.

Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV . When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information Part 2. Full Text of the Announcement I.

Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV.

Application and Submission Section V. Application Review Information Section VI. Award Administration Information Section VII.

Agency Contacts Section VIII. Other Information Full Text of Announcement Section I.

Funding Opportunity Description The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs.

Pain is a critical national health problem; it affects millions of Americans and incurs significant economic costs to society. Pain often results in disability and, even when not disabling, it has a profound effect on the quality of life. Its deleterious effects have been demonstrated in morbidity, immune function, sleep, cognition, eating, mobility, affective state, psychosocial behaviors, and overall functional status.

In the hospitalized patient, pain may be associated with increased length of stay, longer recovery time, and poorer patient outcomes, which in turn have health care quality and cost implications. The NIH Pain Consortium was established in 1996 to enhance pain research and promote collaboration among researchers across the many NIH ICs that have programs and activities addressing pain.

Currently, the research interests of twenty-one NIH Institutes, Centers, and Offices are represented in the Consortium. Although these combined efforts have resulted in great scientific progress, the understanding and treatment of pain remains incomplete.

In 2011, the Institute of Medicine (IOM) released its report, "Relieving Pain in America", which outlined the state of pain prevention, care, and research, and provided a blueprint to guide efforts to transform pain care in the United States. The core recommendations of the IOM report led to development of the National Pain Strategy (NPS), which was released by HHS in 2016.

The NPS outlines the federal government’s first coordinated plan for reducing the burden of chronic pain that affects millions of Americans.

NIH is responsive to and in alignment with the NPS and the IOM report, and continues to be committed to supporting research to advance the scientific understanding of pain and the treatments available to those The NIH Pain Consortium supports research on all conditions in which pain is a prominent feature. Of interest are diseases, such as cancer, that of themselves or their treatment may result in pain.

Many primary conditions, whether acute (such as injury), recurring (such as migraine), or chronic (such as arthritis) are significantly complicated by co-morbid pain disorders. Some pain conditions are unassociated with other primary diagnoses. Chronic pain is widely believed to represent a disease itself, causing long-term detrimental physiologic changes and requiring unique assessments and treatments.

The areas of research detailed below and the following acute and chronic pain conditions are of special interest but do not comprise a comprehensive or complete listing of research areas relevant to this FOA.

Chronic urologic pelvic pain syndromes Musculoskeletal pain, including back pain Cancer related pain (e.g. pain due to metastasis or primary Cardiovascular pain disorders Chemotherapy-induced neuropathies and other related toxicities (e.g. aromatase inhibitor-induced arthralgias).

Temporomandibular joint and muscle disorders Pain associated with HIV/AIDS Pain associated with osteoporosis Pain associated with communication disorders (e.g., otitis media, tinnitus, burning mouth syndrome, dysphagia) Pain in older persons with multiple chronic conditions Pain in people with drug and alcohol addictions Pain in persons with neuromuscular conditions Pain in preterm neonates exposed to multiple medical interventions and/or procedures The R21 mechanism is intended to encourage new exploratory and developmental research projects.

For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area.

These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism.

For example, long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted under this mechanism should be exploratory and novel.

These studies should break new ground or extend previous discoveries toward new directions or New and innovative advances are needed in every area of pain research, from the microperspective of molecular sciences to the macro perspective of behavioral/social sciences.

Although great strides have been made in some areas, such as the neural pathways of pain, chronic pain and the challenge of its treatment have remained uniquely individual and largely unsolved. Applications that seek to improve the understanding of the causes, costs, and societal effects of both acute and chronic pain and the relationships between the two are highly encouraged.

Studies on the mechanisms underlying the transition from acute to chronic pain are also needed. Additionally, applications that link such understandings to the development of better approaches to therapeutic interventions, including complementary and alternative medicine (CAM) interventions, and self-management of acute and chronic pain are in keeping with the current translational focus of NIH and are encouraged.

The following topic areas are not intended to be comprehensive or exhaustive. Synergistic studies that reach across two or more of these areas are encouraged.

Interdisciplinary and multidisciplinary research is especially encouraged, as is research that involves specific cooperation between basic and clinical scientists, incorporates longitudinal and innovative clinical trial designs, and uses comparative effectiveness research techniques. These pain research areas also cut across ICs and programs and should not be viewed as restricted to only one specific IC.

and Cellular Mechanisms of Pain Improved treatments of acute and chronic pain conditions require a thorough understanding of the processes underlying the transmission and perception of painful stimuli. Discovery of the molecules, cells, and neuronal pathways involved in nociception/pain perception and affective aspects of pain are critical.

Molecular and cellular studies, when coupled with studies in animal models and clinical research, will provide a comprehensive basis for the development of new pharmacological, behavioral, and technology-based treatments for chronic pain disorders, and/or research on the mechanisms of action of therapies effective for chronic pain.

Hormones, neurotransmitters and their receptors, ion channels, G-protein coupled receptors, neuropeptides, and neurotrophic factors are just a few of the molecules of interest in pain studies. Molecular mechanisms and nervous system circuitry involved in facilitation and inhibition of pain signaling and in the development of hypersensitive pain states are important targets of pain research.

Neurons, glial cells, and keratinocytes all play important roles in pain sensation and approaches examining their individual functions and their interactions are vital for understanding pain processes. Research is encouraged but not limited to science in the following areas: Mechanisms that underlie sex differences in the pain experience. Cellular and molecular mechanisms involved in pain processing, modulation, and perception.

Molecules and processes that target cellular mechanisms involved in signaling, modulation, and perception of pain, as well as changes in these processes over the developmental life-course, to enhance innovative therapeutic Ontogeny and neuropharmacology of the pain system. Endogenous and environmental factors that alter pain during the course of development, in response to injury, and related to disease processes.

Mechanisms of hypersensitivity including both central and peripheral mechanisms of hyperalgesia and allodynia. Endogenous molecules that modify pain perception and analgesic Clinical studies have identified polymorphisms at several gene loci that are associated with differential sensitivity to experimental pain. Inbred strains of mice also show differential pain responses in models of neuropathic and inflammatory pain.

These studies strongly suggest that genetics plays an important role in pain mechanisms. Chronic pain conditions are complex disorders where environmental and genetic influences interact to affect sensitivity to noxious stimuli and relief from pain. Polymorphisms and mutations in mitochondrial DNA may also play a role in modulating pain, especially in muscles and peripheral nerves.

Elucidating the genetic contributions to the individual variability in pain sensitivity and perception is of much interest. Research is encouraged but not limited to science in the Genes and gene variants involved in the complex processes of pain Genome-wide screens for polymorphisms associated with increased risk for onset, development and persistence of pain disorders.

Utilization of pharmacogenetics to identify gene variants with potential to inform treatment providers which pain medications may be most effective for the individual needing therapy, with the fewest side effects. Use of gene therapy to ameliorate chronic pain. Gene polymorphisms and gene-environment interactions that predict pain development or treatment response.

Epigenetic mechanisms underlying chronic pain conditions. The experience of pain is a complex interaction of biological, cognitive, behavioral, sociocultural, spiritual, and environmental factors. Pain etiology, severity, tolerance, exacerbation, maintenance, and treatment are all significantly influenced by this complex of acknowledged but poorly understood interactions.

Comorbid conditions that alter affect, such as mood disorders, can induce or exacerbate pain. Although it is recognized that psychological factors, such as expectation or stress, significantly contribute to pain tolerance and treatment efficacy, the physiological mechanisms of these effects are poorly understood.

Physiologic responses such as autonomic arousal, muscle tone and activity, skin thermal receptor activation, and cardiopulmonary reactivity, are perceived as painful in some behavioral and sociocultural environments, but not in others.

The elucidation of these complex interactions will enable better assessment of pain in clinical settings, more effective therapeutic approaches, greater ability to prevent pain onset, and potentially will increase the individual's ability to Research is encouraged but not limited to science in the Adaptation to pain and ways to incorporate this adaptation into Mechanisms and process variables that are responsible for the efficacy of behavioral and CAM interventions for pain.

This research includes studies to better understand the effect of patients' expectations and beliefs, psychophysiological states (e.g., anxiety, relaxation, stress), adherence, and specific cognitive (e.g., imagery) and sociocultural (e.g., support systems) components in behavioral and CAM interventions to treat pain. Biobehavioral techniques for optimizing adherence to pain management.

Identify and reduce barriers to adherence to pain management Sensory, cognitive, and affective aspects of acute and chronic pain in individuals across the lifespan. Development of methods for assessing relative contributions of biological, psychological, behavioral, and environmental predictors of the course of pain, pain dysfunction, and response to treatment for pain.

Interactions of pain and sleep, their combined impact on function and illness recovery, and interventions that target these interactions.

Relationships among a variety of emotional states (e.g., anger, fear, anxiety and depression), which are associated with acute and chronic pain conditions, and how these affective states modify the experience of pain and Interaction of biological markers, central nervous system mechanisms, and drug, behavioral, and CAM interventions.

Mechanisms that underlie gender and cultural differences in the There are many factors responsible for pain experienced by patients. Current animal models of pain have been useful in understanding the mechanisms of pain and developing interventions that target these particular mechanisms. However, many of the existing animal models do not adequately reflect clinical pain conditions and, in particular, chronic pain disorders.

The development of new animal models is necessary in order to discover the underlying mechanisms of pain perception as well as the mechanisms of analgesia that will prove useful in treating patients. Innovative clinical modeling studies are also needed to advance our understanding of these underlying mechanisms. Research is encouraged but not limited to science in the following New animal models and refinement of existing animal models.

New measures of pain in animals that are non-invasive and objective, and that permit a behavioral or functional assessment of pain and Use of transgenic animals in the study of pain mechanisms. Studies in patients with chronic pain conditions that develop, test, and validate new models of these chronic disorders.

Computational models that predict development of pain and/or Computer simulations of pain that overcome ethical concerns and expand the range of studies possible.

System models to improve understanding of pain and treatment integrating multiple layers of biological and behavioral sciences (e.g. across domains of genes, neuron, brain, behavior, family/social/work/environment and Objective Measures of spontaneous pain in validated animal models of chronic pain conditions. Most healthcare system interactions are initiated by persons with complaints of pain.

To date, direct patient report is the basis of most pain assessments.

Yet many patients, including the very young, persons with cognitive, sensory, psychiatric, or physical disabilities, those rendered unresponsive by their physiologic state (e.g., drug intoxication, severe brain injury), and those persons who by culture, education, language, or communication skills may be unable to effectively respond using currently validated assessment tools.

To study, model, predict, prevent, diagnose, treat, or manage pain effectively, sensitive multimodal measurement tools are needed. Pain assessment techniques must be valid and reliable and provide sensitivity, both with single and repeated measurements, and allow for the assessment of acute, chronic, persistent, and breakthrough pain.

Severity/intensity, type/location/source (i.e., somatic, visceral, neuropathic), and duration (acute, chronic, persistent, breakthrough) are key components to assess. Assessment should include diagnostic as well as outcomes measures. Research is encouraged but not limited to science in the following areas: Refinement of existing physiologic techniques for measuring pain for greater sensitivity and specificity.

New, outcome-specific techniques for different populations. Sensitive assessment tools that are not language (neither receptive nor production) dependent. Refinement of pain measurements that can account for or predict the trajectory or course of pain, as well as the changes in pain over time.

Predictive biomarkers and biosignatures of pain that are sensitive to rapid changes in pain. Develop pain assessments that are sensitive across both developmental and cognitive spectrums, especially assessments of pain in children and in older adults with declining cognitive function.

New technologies to improve pain assessment in all populations, but especially in those persons with limited language abilities or those unable Use of Patient Reported Outcomes Measurement Information System (PROMIS) measures for quantifying pain interference, behavior and The prevalence of pain and inadequate pain management in patients is well documented.

It is estimated that 75% of patients with advanced cancer experience moderate to severe pain; an IOM report states that 40% of people at the end of life have severe, unrelieved pain. A number of advances have been made in the treatment of chronic pain, most notably the neuroactive medications, counter-stimulation methods, and cognitive-behavioral therapies. However, adoption of these advances remains modest.

Many patients report that they are reluctant or afraid to report their pain, are unaware of available pain management modalities, or do not adhere to pain treatment when available. Healthcare providers undertreat pain, fearing patient addiction, drug interactions, or adverse events.

In addition, research findings consistently show the heterogeneity of response to treatment, even for pain of the same type Due to the biobehavioral nature of pain, pain management should engage interdisciplinary teams and involve both pharmacologic and non-pharmacologic approaches and self-management strategies.

Longitudinal research in pain to include comparative effectiveness research and novel randomized controlled trials will ensure patients receive pain care that works best in the short and long term.

Research is encouraged but not limited to science in the following areas: Interventions involving combinations and sequencing of pharmacological, non-pharmacological, self-management and behavioral interventions to manage pain in progressive, incurable diseases. Interventions to reduce pain that are customized to the group (i.e., targeted), as well as to the individual (i.e., tailored).

New methods to manage pain in cognitively impaired individuals or those unable to verbalize their pain. Interventions to manage co-occurring symptoms related to pain such as depression and fatigue. Role of pain and pain management approaches in improving rehabilitation outcomes and preventing functional decline.

Role of pain and pain management approaches on population health outcomes, utilization and cost Methods for optimizing maintenance and stability of treatment in patients with advancing disease or with pain from multiple contributing disease Novel interventions to manage pain in progressive, incurable, Novel interventions to manage metastatic cancer pain which is progressive and incurable.

Interventions to improve management of side-effects related to pharmacological pain therapy or to address interactions between therapeutics for pain and other diseases of their treatments. New techniques for managing pediatric pain. Models of therapy in those with uncontrolled pain and/or Pain management strategies at the end of life.

Long-term (i.e., physiologic, behavioral, or developmental) effects of pharmacologic treatment during the neonatal period and childhood. Long term efficacy of existing pain therapies (e.g. chronic opiod Clinical trials to establish best pain management practices. Evaluation of pain management for acute trauma prior to transport Pain management in individuals with multiple chronic conditions.

One goal of this FOA is to stimulate innovative investigations that enhance our understanding of the incidence, prevalence, and correlates of pain within and across populations. Epidemiology is one of the fields of science recognized for its contribution to understanding of physical and mental disorders. However, epidemiologic information concerning pain disorders is not well developed.

Research is encouraged but not limited to science in the following areas: Incidence and natural history of pain disorders and their Interplay of environmental (e.g., familial and/or neighborhood quality and resources), physical (e.g., co-morbid medical disorders that are a result of, or a cause of pain), behavioral (e.g., co-morbid mental and substance use disorders), and social or socio-economic (e.g., loss of employment-including issues of secondary or tertiary gain, social isolation, lack of mobility, dependence on others for basic caretaking) factors.

Risk factors; including age, ethnicity, family history, gender, genetic predisposition, lifestyle, occupation, pre- or co-existing mental and physical disorders, and socio-economic status (SES); and the mechanisms that are associated with the occurrence, maintenance, and remission of pain conditions.

Impact of pain on an individuals SES and the resulting health consequences (e.g., obesity, deconditioning, mental disorders, substance abuse) controlling for the effect of the cultural and socio-economic influence of the Prevalence of and methods for self-management of pain within and across cultural, racial, ethnic populations, and populations of special interest such as persons with disabilities, across age groups.

The effect changes in practice or policy have on the measures of pain, e.g., effect of the increase in the amount of opioid prescriptions on the natural course of pain using aggregate population measures. Creation and adoption of innovative epidemiologic and statistical methodologies and study designs to further the understanding of pain disorders.

Also use these techniques to maximize the analytic yield from new and existing Interrelationship of psychiatric disorders (e.g., borderline personality, histrionic, antisocial) and chronic pain, and relate these findings to pharmacological and behavioral therapies.

Co-morbid disorders and pain, including descriptive studies of risk and protective processes, and interventions aimed at relieving adverse consequences associated with co-morbid disorders and pain. The Institute of Medicine reported significant racial and ethnic disparities with regard to the socioeconomic, health, and quality-of-life impacts of pain.

Racial and ethnic minorities tend to be under treated for pain when compared with non-Hispanic Whites. There is also evidence for racial/ethnic differences in pain care for various types of pain. Persons with disabilities report greater levels of pain and less benefit from treatment than do those without disabilities.

Little other data exists as to pain disparities in persons with disabilities, the homeless, or persons living in frontier/extremely rural areas. It is clear that many factors contribute to these health disparities, including patient preferences, differences in attitudes toward and response to treatments, access to and accessibility of health care providers, and health care system factors.

This program announcement invites research applications that seek to address the underlying causes of these disparities and suggest ways to address and remedy them. In particular, clinical investigations and appropriate clinical trials relevant to health disparity issues are of interest.

Research is encouraged but not limited to science in the following areas: Differences in care for various types of pain, acute postoperative pain, treatment-related pain, cancer pain, or chronic non-malignant pain, in various settings (i.e., health clinics, physician and dental offices, institutional settings including long-term care facilities, assisted living facilities, or emergency departments), and management of pain Differences in the factors contributing to pain disparities including patient-related (e.g., communication, attitudes), health care provider-related (e.g., decision making), and health care system-related (e.g., access to pain medication) factors.

Differences in perceptions of pain and responses to pain and how these differences impact appropriate treatment management of pain. The nature and extent of disparities in the delivery of pain treatment in diverse populations. Existing and potential barriers to quality pain care and management including patient-related barriers, health care provider-related barriers, health care system-related barriers, and sociocultural barriers.

Novel, evidence-based interventions to improve training for health care providers and educational interventions for minority patients. Measures of pain perception for those with cognitive impairment, or limited health literacy and from varied cultures.

Assessment of the global impact, including societal and medical consequences, of pain related disparities on both individuals and society, and the potential impact of pain-related disability. Diverse cultural beliefs about and actions taken for pain and its management including self-care and that of lay caregivers.

Treatment and management strategies for chronic pain in diverse Means to identify population differences in pain perception and processing by addressing the incidence, severity, and consequences of pain in these and the general populations, and in specific disease states. New diagnostic tools for different pain mechanisms, and objective measures of treatment response that have validity in diverse populations.

The prevalence and effectiveness of the use of non-pharmacological and novel (e.g. virtual reality) therapies for pain treatment in diverse populations such as ethnic minority groups and persons Pain management for special populations including infants, children, elderly, cognitively impaired, disabled, chronically and/or terminally ill, and patients with psychiatric diagnoses.

The translation of laboratory-based, scientific discoveries into practical, clinical applications is a current priority for NIH. Such translational research has a reasonable probability of leading to practical outcomes within the foreseeable future and likewise resultant clinical findings should stimulate new areas of basic research.

Inherent in translational research is the recognition of both efficacy (i.e., does the intervention work in a controlled setting) and effectiveness (i.e., does the intervention work in the natural environment) research. Effective translational research is extremely important in pain research and is needed to bridge the inherent differences in approach between basic studies of pain and the clinical study of pain conditions.

Accordingly, applications directed toward translational pain research are of particular interest. Research is encouraged but not limited to science in the following areas: Novel pharmacological and non-pharmacological pain treatments and self-management pain strategies. Improved treatment protocols and adjunctive therapies that promote greater effectiveness, self-management, patient adherence or tolerance.

Characteristics (e.g., gender, race, age, type of pain) that predict which patient populations will benefit most or least from various pain Barriers to effective pain treatment. New technologies for use in the study and treatment of pain in the natural environment of the patient’s daily living. Clinical studies to inform, develop, and validate new animal models of chronic pain conditions; i.e. a bedside to bench approach.

Design and development of small molecule mimics and other advanced pharmacological approaches. Specific to NIAMS: Applicants who wish to submit clinical trial applications for consideration by NIAMS should not submit the application to this FOA. Instead, applicants are encouraged to submit clinical trial applications to one of the FOAs listed at http://www.

niams. nih. gov/Funding/Clinical_Research/clinical_main.

asp . Specific to NINDS: NINDS will not accept clinical trials under this FOA. Applicants submitting applications to NINDS which contain a clinical trial must submit to one of the NINDS FOAs specifically designed for clinical trials (see: http://www.

ninds. nih. gov/research/clinical_research/index.

htm ).

Specific to NCCIH: For this FOA, NCCIH will only support the following types of research: 1) basic and mechanistic studies to examine the impact of complementary health approaches on pain in cellular systems or model organisms; 2) mechanistic studies in humans to investigate the processes by which complementary health approaches exert their effects on pain and clinical conditions that often co-occur with pain; or 3) basic, mechanistic, or translational studies of phytocannabinoids and their derivatives for pain.

NCCIH is not interested in applications of human clinical studies or trials that propose primary aims to evaluate efficacy or effectiveness. Investigators are encouraged to consult NCCIH Scientific/Research staff to identify NCCIH-specific FOAs to support clinical studies or trials that propose to measure the clinical impact of complementary or integrative See Section VIII.

Other Information for award authorities Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. Application Types Allowed Glossary and the SF424 (R&R) Application Guide provide details on Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single The scope of the proposed project should determine the project period. The maximum project period is 2 years. Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Nonprofits without 501(c)(3) IRS Status (Other than Institutions For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Non-domestic (non-U.S.) Entities (Foreign Institutions) Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible